2024-10-18 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational healthcare company that develops, manufactures, and sells a wide range of pharmaceuticals, medical devices, and consumer healthcare products. Compared to the S&P 500 (VOO), JNJ has significantly underperformed. The cumulative return for JNJ is 37.1%, while the S&P 500 has returned 136.93%. This results in a cumulative return difference of -99.83%, placing it at the 4.96th percentile of its historical performance range.

**2. Recent Price Movements:**

As of today, JNJ's closing price is $164.28. The 5-day moving average is $162.38, the 20-day moving average is $161.87, and the 60-day moving average is $162.23. This indicates a slightly bullish trend in the short-term, with the price trading above all moving averages.

**3. Technical Indicators:**

* **RSI:** 64.73 - This suggests the stock is currently in overbought territory, indicating potential for a short-term correction.
* **PPO:** 0.18 - This shows a positive momentum, but it's relatively low, indicating that the momentum is not very strong.
* **Delta_Previous_Relative_Divergence:** -8.05 - This signifies a short-term downward trend in relative strength compared to the S&P 500.
* **Expected Return:** 0.0% - The expected return for the next 5 years is 0%, indicating that JNJ's future performance is expected to be similar to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date         | EPS   | Revenue         |
|--------------|-------|-----------------|
| 2024-07-25   | 1.95  | $22.45 B      |
| 2024-05-01   | 1.35  | $21.38 B      |
| 2024-02-16   | 1.68  | $21.39 B      |
| 2023-10-27   | 10.32 | $21.35 B      |
| 2024-02-16   | 10.32 | $21.35 B      |

The most recent earnings report (2024-07-25) shows that JNJ beat EPS estimates, but the revenue was slightly below expectations.  Despite this, JNJ's earnings have remained stable in recent quarters.

**5. News and Recent Issues:**

Recent market outlook for JNJ remains cautiously optimistic. Analysts are generally impressed by JNJ's consistent performance and robust dividend payments. However, concerns remain regarding the impact of a challenging macroeconomic environment on consumer spending, which could affect JNJ's consumer healthcare business.

**6. Overall Analysis:**

JNJ is a mature company with a solid track record of dividend payouts and consistent earnings. Despite its recent underperformance compared to the S&P 500, it maintains a strong position in the healthcare sector. The recent earnings beat and stable performance indicate a positive outlook for the company. However, the overbought RSI and negative relative divergence signal potential short-term weakness. Investors should consider these factors before making any investment decisions.

**7. Recommendation:**

JNJ is a solid company with a history of stability and growth. However, its current valuation and underperformance compared to the broader market warrant caution. Investors seeking a steady and dependable dividend income stream might find JNJ attractive. However, those seeking aggressive growth might consider alternative investment options. 
